|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Importance of fatigue and its measurement in chronic liver disease显示文摘The mechanisms of fatigue in the group of people with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are protean. The liver is central in the pathogenesis of fatigue because it uniquely regulates much of the storage, release and production of substrate for energy generation. It is exquisitely sensitive to the feedback controlling the uptake and release of these energy generation substrates. Metabolic contributors to fatigue, beginning with the uptake of substrate from the gut, the passage through the portal system to hepatic storage and release of energy to target organs (muscle and brain) are central to understanding fatigue in patients with chronic liver disease. Inflammation either causing or resulting from chronic liver disease contributes to fatigue, although inflammation has not been demonstrated to be causal. It is this unique combination of factors, the nexus of metabolic abnormality and the inflammatory burden of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that creates pathways to different types of fatigue. Many use the terms central and peripheral fatigue. Central fatigue is characterized by a lack of self-motivation and can manifest both in physical and mental activities. Peripheral fatigue is classically manifested by neuromuscular dysfunction and muscle weakness. Therefore, the distinction is often seen as a difference between intention (central fatigue) versus ability (peripheral fatigue). New approaches to measuring fatigue include the use of objective measures as well as patient reported outcomes. These measures have improved the precision with which we are able to describe fatigue. The measures of fatigue severity and its impact on usual daily routines in this population have also been improved, and they are more generally accepted as reliable and sensitive. Several approaches to evaluating fatigue and developing endpoints for treatment have relied of biosignatures associated with fatigue. These have been used singly or in combination and include: physical performance measures, cognitive performance measures, mood/behavioral measures, brain imaging and serological measures. Treatment with non-pharmacological agents have been shown to be effective in symptom reduction, whereas pharmacological agents have not been shown effective. | Lynn H Gerber Ali A Weinstein Rohini Mehta Zobair M Younossi | 2019 | World Journal of Gastroenterology2019，25，28： | 7 |
| 2 | 以肝脏为靶器官的基因治疗时重组腺病毒引起的急性肝炎显示文摘目的 研究腺病毒为载体的基因治疗时淋巴细胞在肝组织免疫反应中的作用,探讨免疫抑制疗法在腺病毒载体基因治疗中的可行性。 方法 取8只恒河猴,经不同路径输入携带大肠杆菌lacZ基因或荧火虫荧光素酶基因luc的重组腺病毒6只。其中4只进行免疫抑制治疗。将含lacZ的质粒DNA注入2只动物作为对照。用免疫组织化学法检测β2-MG、HLA-DR、CD3、CD4、CD8及CD20。 结果 腺病毒介导的基因治疗时肝脏的β2-MG、HLA-DR、CD3、CD4及CD8阳性细胞明显增多。腺病毒载体和转基因均与肝损害有关, 表现为一过性, 呈轻、中度无黄疸性肝炎。免疫抑制的动物只要处于免疫抑制状态下就没有肝炎的表现,基因表达的时间延长。质粒介导的基因转导效果差, 无肝损害及免疫反应。所有动物B淋巴细胞抗原CD20始终阴性。 结论 腺病毒介导的基因治疗时肝脏的β2-MG、HLA-DR、CD3、CD4及CD8阳性细胞明显增多, 造成轻、中度一过性肝损害。使用免疫抑制药物可避免肝损害的发生并延长基因表达的时间。 | 鲁慧英 Deborah Sullivan Srikanta Dash Michael A Gerber | 2001 | 中华肝脏病杂志2001，9，5： | 3 |
| 3 | CA6NM: New developmentsbased on 20 years experience 显示文摘 | Gysel W Gerber E Trautwein A | 1982 | Stainless Steel Castings1982，，3： | 2 |
| 4 | Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence显示文摘BACKGROUND Patients with an in-breast tumor recurrence(IBTR)after breast-conserving therapy have a high risk of distant metastasis and disease-related mortality.Classifying clinical parameters that increase risk for recurrence after IBTR remains a challenge.AIM To describe primary and recurrent tumor characteristics in patients who experience an IBTR and understand the relationship between these characteristics and disease outcomes.METHODS Patients with stage 0-II breast cancer treated with lumpectomy and adjuvant radiation were identified from institutional databases of patients treated from 2003-2017 at our institution.Overall survival(OS),disease-free survival,and local recurrence-free survival(LRFS)were estimated using the Kaplan Meier method.We identified patients who experienced an isolated IBTR.Concordance of hormone receptor status and location of tumor from primary to recurrence was evaluated.The effect of clinical and treatment parameters on disease outcomes was also evaluated.RESULTS We identified 2164 patients who met the eligibility criteria.The median follow-up for all patients was 3.73[interquartile range(IQR)2.27-6.07]years.Five-year OS was 97.7%(95%CI:96.8%-98.6%)with 28 deaths;5-year LRFS was 98.0%(97.2-98.8)with 31 IBTRs.We identified 37 patients with isolated IBTR,19(51.4%)as ductal carcinoma in situ and 18(48.6%)as invasive disease,of whom 83.3%had an in situ component.Median time from initial diagnosis to IBTR was 1.97(IQR:1.03-3.5)years.Radiotherapy information was available for 30 of 37 patients.Median whole-breast dose was 40.5 Gy and 23 patients received a boost to the tumor bed.Twenty-five of thirty-two(78.1%)patients had concordant hormone receptor status,HER-2 receptor status,and estrogen receptor(ER)(P=0.006)and progesterone receptor(PR)(P=0.001)status from primary to IBTR were significantly associated.There were no observed changes in HER-2 status from primary to IBTR.The concordance between quadrant of primary to IBTR was 10/19[(62.2%),P=0.008].Tumor size greater than 1.5 cm(HR=0.44,95%CI:0.22-0.90,P=0.02)and use of endocrine therapy upfront(HR=0.36,95%CI:0.18-0.73,P=0.004)decreased the risk of IBTR.CONCLUSION Among patients with early stage breast cancer who had breast conserving surgery treated with adjuvant RT,ER/PR status and quadrant were highly concordant from primary to IBTR.Tumor size greater than 1.5 cm and use of adjuvant endocrine therapy were significantly associated with decreased risk of IBTR. | Juhi M Purswani Fauzia Shaikh S Peter Wu Jennifer Chun Kim Freya Schnabel Nelly Huppert Carmen A Perez Naamit K Gerber | 2020 | World Journal of Clinical Oncology2020，11，1： | 2 |
| 5 | Representing polydispersed droplet behavior in nucleating steam flow 显示文摘 | GERBER A G MOUSAVI A | 2007 | Journal of Fluids Engineering2007，129，11： | 1 |
| 6 | Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics 显示文摘 | Lampertico P Maher J S Gerber M A | 1991 | Hepatology1991，13，3： | 1 |
| 7 | Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patient after acute myocardial infarction显示文摘 | Gerber B L Garot J Bluemke D A | 2002 | Circulation2002，106，： | 1 |
| 8 | Carcinogenicity,mutagenicity and teratogenicity of manganese compounds显示文摘 | Gerber G B Leonard A Hantson P | 2002 | Critical Reviews in Oncology/Hematology2002，42，： | 1 |
| 9 | Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcuspneumoniae meningitis显示文摘 | BOTTCHER T GERBER J WELLMER A | 2000 | J Infect Dis2000，181，20： | 1 |
| 10 | Numerical investigation of the influence of rock shape on rockfall trajectory显示文摘 | Glover J Schweizer A Christen M Gerber W Leine R Bartelt P | 2012 | Geophysical Research Abstracts2012，14，11： | 1 |
| 11 | Quantitative analysis of complex protein mixtures using isotope -coded affinity tags显示文摘 | GYGI S P RIST B GERBER S A | 1999 | Nat Biotechnol1999，17，10： | 1 |
| 12 | Gravity gradiometry 显示文摘 | Gerber M A | 1978 | Astronautics and Aeronau- tics1978，16，： | 1 |
| 13 | l Progressive loss of PAX9 expression correlates with increasing malignancy of dysplastic and cancerous epithelium of the human esophagus 显示文摘 | Gerber JK RichterT KremmerE et a | 2002 | J Patho2002，197，3： | 1 |
| 14 | VEGF regulateshaematopoietic stem cell survival by an internal autocrine loopmechanism显示文摘 | Gerber H P Malik A K Solar G P | 2002 | Nature2002，417，6892： | 1 |
| 15 | Validation of an immunoperoxidase monolayer assay for total anti-Vac- cinia virus antibody titration 显示文摘 | Gerber P F Matos A C Guedes M I | 2012 | J Vet Diagn Invest2012，24，2： | 1 |
| 16 | Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction显示文摘 | GERBER B L ROCHITTE C E MELIN J A | 2000 | Circulation2000，101，： | 1 |
| 17 | Cathepsin K-a marker of macrophage differentiation 显示文摘 | Buhling F Reisenauer A Gerber A | 2001 | J Pathol2001，195，3： | 1 |
| 18 | Genetic applications of an inverse polymerase chain reaction 显示文摘 | Ochman H Gerber A S Hartl D L | 1988 | Genetics1988，120，： | 1 |
| 19 | Measurement of myocardial infarct size by electron beam computed tomography:a comparison with 99mTc sestamibi显示文摘 | Schmermund A Gerber T Behrenbeck T | 1998 | Invest Radiol1998，33，6： | 1 |
| 20 | Diagnosis, treatment, and long-term management of Kawasakidisease ; a statement for health professionals from the Committeeon Rheumatic Fever, Endocarditis and Kawasaki Disease,Council on Cardiovascular Disease in the Young, AmericanHeart Association 显示文摘 | NEWBURGER J W TAKAHASHI M GERBER M A | 2004 | Circulation2004，110，17： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员